BOCA RATON, Fla., Oct. 17 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Henrik Rasmussen, M.D.,
Ph.D., senior vice president, clinical, medical and regulatory affairs, will
be presenting at the CEUT Emerging Growth Life Sciences Conference on Tuesday,
October 25, 2005 at 2:40 pm ET at the New York Palace Hotel, Room A, 455
Madison Avenue, New York, New York. Dr. Rasmussen's presentation will focus
on the company, its products and its progress.
The presentation will be webcast live at:
http://www.wsw.com/webcast/ceut3/nabi .
The webcast will be available through November 25, 2005.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are poised to capture large commercial opportunities in our
core business areas: Gram-positive bacterial infections, hepatitis, kidney
disease (nephrology), and opportunistically in nicotine addiction. We have
three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium
(for injection)] and a number of products in various stages of clinical and
preclinical development. The company filed its Marketing Authorization
Application (MAA) in Europe for its product candidate, StaphVAX(R)
[Staphylococcus aureus Polysaccharide Conjugate Vaccine], in December 2004.
The application was accepted for review in January 2005. StaphVAX is
currently in a confirmatory Phase III clinical trial in the U.S. StaphVAX is
designed to prevent the most dangerous and prevalent strains of S. aureus
bacterial infections. S. aureus bacteria are a major cause of hospital-
acquired infections and are becoming increasingly resistant to antibiotics.
The company also filed MAAs in Europe to market Nabi-HB(R) Intravenous
[Hepatitis B Immune Globulin (Human) Intravenous] under the trade name
HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver
transplant patients; and for PhosLo(R) (calcium acetate), which is already
marketed in the U.S. The company's other products in development include
Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], an
antibody for prevention and treatment of S. aureus infections, NicVAX(TM)
[Nicotine Conjugate Vaccine], a vaccine to treat nicotine addiction, and
Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing
hepatitis C virus re-infection in liver transplant patients. For additional
information on Nabi Biopharmaceuticals, please visit our website at:
http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
Audio:http://www.wsw.com/webcast/ceut3/nabi
CONTACT:
Constance C. Bienfait, Vice President,
Investor Relations, Nabi, +1-561-989-5800
|
